Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms

Sisi Wu, Xiaoxiao Wang, Mingming Tong, Fu Li, Yanjing Zhang, Jiayi Xu, Xuemei Chen, Hongying Chen, Ruli Li, Yao Wu, Juan-Juan Xin, Xin Yan, He Li, Jie Lan, Kunyue Xue, Xue Li, Caili Zhuo, Wei JiangResearch 2021 · DOI

Introduction

Doxorubicin (DOX) remains a cornerstone of modern oncology, yet its clinical utility is frequently compromised by severe cardiotoxic side effects. This toxicity often manifests as permanent damage to cardiomyocytes, potentially progressing to congestive heart failure. While the generation of reactive oxygen species (ROS) and subsequent cell death are known drivers of DOX-induced cardiotoxicity, the precise molecular regulators that might mitigate this damage have remained largely unidentified. Recent research has highlighted Sirt6, a member of the sirtuin family of NAD+-dependent deacetylases, as a critical candidate for cardiac protection.

The Role of Sirt6 in Cardiac Homeostasis

Sirt6 is primarily recognized for its roles in DNA repair, metabolic regulation, and aging. In the context of the heart, Sirt6 acts as a critical epigenetic regulator. This study investigates how Sirt6 influences the fate of cardiomyocytes under the stress of DOX treatment, specifically focusing on its ability to modulate oxidative stress and programmed cell death pathways.

Experimental Methodology

To elucidate the protective mechanisms of Sirt6, researchers employed a dual-model approach combining in vivo and in vitro techniques:

  • Animal Models: The team used heterozygous Sirt6 knockout ($Sirt6^{+/-}$) mice and their wild-type (WT) littermates, subjecting them to a five-week DOX protocol to simulate clinical cardiotoxicity.
  • Cell Culture: Neonatal rat cardiomyocytes (NRCMs) were used to observe molecular interactions. Techniques such as siRNA-mediated silencing and adenoviral-mediated overexpression allowed researchers to manipulate Sirt6 levels directly.
  • Molecular Analysis: The team utilized Chromatin Immunoprecipitation (ChIP) and Co-Immunoprecipitation (Co-IP) to map the physical and functional interactions between Sirt6 and other regulatory proteins, specifically the tumor suppressor p53.

Key Insights: The Sirt6-p53 Regulatory Axis

The study's most significant finding is the identification of a "molecular handshake" between Sirt6 and p53. Under DOX-induced stress, p53 typically activates the transcription of "death genes" like Fas and FasL. However, Sirt6 acts as a co-repressor, binding to p53 and preventing it from initiating this pro-apoptotic program.

Sirt6 achieves this through epigenetic modification. As a deacetylase, it removes acetyl groups from Histone H3K9 at the promoter regions of the Fas and FasL genes. This deacetylation "locks" the chromatin structure, making the DNA inaccessible for transcription and effectively silencing the cell death signal.

Dual-Path Protection Against Cell Death

By inhibiting the Fas/FasL signaling system, Sirt6 provides a comprehensive shield against two distinct forms of cell death:

  1. Apoptosis: Sirt6 reduces the activation of Caspase-8, a key executioner of programmed cell death.
  2. Necrosis: Sirt6 attenuates the RIP3-mediated necrotic pathway, which is often triggered by the same Fas/FasL signals.

Furthermore, Sirt6 reinforces the heart's natural defenses by upregulating endogenous antioxidants, including Superoxide Dismutase 2 (SOD2) and Catalase. This dual action—blocking death signals while boosting antioxidant capacity—significantly reduces the oxidative burden on the heart.

Results and Clinical Implications

The experimental results were striking. In the mouse models, the survival rate following DOX treatment was 76.3% in wild-type mice, compared to only 46.5% in Sirt6-deficient mice. Those lacking sufficient Sirt6 also exhibited significantly worse cardiac output, lower ejection fractions, and increased myocardial fibrosis (scarring).

Molecular analysis confirmed that DOX treatment naturally depletes Sirt6 levels in the heart by approximately 39.5% to 74.8%. However, restoring Sirt6 levels via adenoviral vectors successfully reversed much of the damage, reducing markers of both apoptosis (cleaved Caspase-3) and necrosis (HMGB1).

Conclusion and Future Directions

This research identifies Sirt6 as a vital molecular brake on the cardiotoxic effects of doxorubicin. By epigenetically silencing p53-mediated death pathways and bolstering antioxidant defenses, Sirt6 preserves cardiomyocyte integrity and cardiac function.

While these results are promising in rodent models, translating them to human patients requires further investigation. Future work must determine how to safely boost Sirt6 activity in cancer patients without interfering with the chemotherapy's primary goal of eliminating tumor cells. Nonetheless, Sirt6 emerges as a promising therapeutic target for preventing heart failure in cancer survivors.

Summary updated

Abstract

Abstract Sirt6, a class III NAD + -dependent deacetylase of the sirtuin family, is a highly specific H3 deacetylase and plays important roles in regulating cellular growth and death. The induction of oxidative stress and death are the crucial mechanisms involved in cardiomyocyte damage and cardiac dysfunction in doxorubicin-induced cardiotoxocity, but the regulatory role of Sirt6 in the fate of DOX-impaired cardiomyocytes is poorly understood. In this study, we exposed heterozygous Sirt6 knockout (Sirt6 +/− ) mice and their littermates as well as cultured neonatal rat cardiomyocytes to DOX, then investigated how Sirt6 mitigates oxidative stress and myocardial injury in the DOX-treated myocardium. Sirt6 partial knockout or silencing worsened myocardial damage, cardiac remodeling, and oxidative stress in mice or cultured cardiomyocytes with DOX challenge. Cardiomyocytes infected with adenoviral constructs encoding Sirt6 showed reversal of this DOX-induced damage. Intriguingly, Sirt6 reduced oxidative stress injury by upregulating endogenous antioxidant levels, interacted with oxidative stress-stirred p53, and acted as a co-repressor of p53 in nuclei. Sirt6 was recruited by p53 to the promoter regions of the target genes Fas and FasL and further suppressed p53 transcription activity by reducing histone acetylation. Sirt6 inhibited Fas/FasL signaling and attenuated both Fas-FADD-caspase-8 apoptotic and Fas-RIP3 necrotic pathways. These results suggest that Sirt6 protects the heart against DOX-induced cardiotoxity by upregulating endogenous antioxidants, as well as suppressing oxidative stress and cell death signaling pathways dependent on ROS-stirred p53 transcriptional activation, thus reducing Fas-FasL–mediated apoptosis and necrosis.
BibTeX
@inproceedings{wu2021sirt,
  author = {Sisi Wu and Xiaoxiao Wang and Mingming Tong and Fu Li and Yanjing Zhang and Jiayi Xu and Xuemei Chen and Hongying Chen and Ruli Li and Yao Wu and Juan-Juan Xin and Xin Yan and He Li and Jie Lan and Kunyue Xue and Xue Li and Caili Zhuo and Wei Jiang},
  title = {{Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-263382/v1},
}
Figure